LU92389I2 - Cystéamine - Google Patents

Cystéamine Download PDF

Info

Publication number: LU92389I2
Authority: LU; Luxembourg
Prior art keywords: cysteamine
Prior art date: 2006-01-27

Application number

LU92389C

Other languages

English (en)

Original Assignee

Univ California

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-01-27

Filing date

2014-03-05

Publication date

2015-10-29

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38327943&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LU92389(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2014-03-05 Application filed by Univ California filed Critical Univ California

2015-10-29 Publication of LU92389I2 publication Critical patent/LU92389I2/fr

Links

UFULAYFCSOUIOV-UHFFFAOYSA-N cysteamine Chemical compound NCCS UFULAYFCSOUIOV-UHFFFAOYSA-N 0.000 title 1
229960003151 mercaptamine Drugs 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/2873—Proteins, e.g. gelatin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/288—Compounds of unknown constitution, e.g. material from plants or animals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
- A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5052—Proteins, e.g. albumin
- A61K9/5057—Gelatin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5063—Compounds of unknown constitution, e.g. material from plants or animals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Epidemiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Zoology (AREA)
Botany (AREA)
Psychology (AREA)
Nutrition Science (AREA)
Physiology (AREA)
Toxicology (AREA)
Psychiatry (AREA)
Hospice & Palliative Care (AREA)
Gastroenterology & Hepatology (AREA)
Obesity (AREA)
Hematology (AREA)
Diabetes (AREA)
Biochemistry (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicinal Preparation (AREA)

LU92389C 2006-01-27 2014-03-05 Cystéamine LU92389I2 (fr)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US76271506P	2006-01-27	2006-01-27
PCT/US2007/002325 WO2007089670A2 (fr)	2006-01-27	2007-01-26	Cystéamine à enrobage entérique, cystamine et leurs dérivés

Publications (1)

Publication Number	Publication Date
LU92389I2 true LU92389I2 (fr)	2015-10-29

Family

ID=38327943

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
LU92389C LU92389I2 (fr)	2006-01-27	2014-03-05	Cystéamine

Country Status (20)

Country	Link
US (15)	US8026284B2 (fr)
EP (3)	EP2535044B1 (fr)
AU (1)	AU2007210005C1 (fr)
BR (1)	BRPI0707277B1 (fr)
CA (1)	CA2640531C (fr)
CY (1)	CY1122943T1 (fr)
DK (2)	DK2535044T3 (fr)
EA (2)	EA023971B1 (fr)
ES (2)	ES2388310T7 (fr)
FR (1)	FR14C0018I1 (fr)
HU (1)	HUE049307T2 (fr)
IL (1)	IL193044A (fr)
LT (1)	LT2535044T (fr)
LU (1)	LU92389I2 (fr)
MX (2)	MX382184B (fr)
NL (1)	NL300649I2 (fr)
PL (2)	PL1919458T6 (fr)
PT (2)	PT2535044T (fr)
SI (2)	SI2535044T1 (fr)
WO (1)	WO2007089670A2 (fr)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2388310T7 (es)	2006-01-27	2017-05-03	The Regents Of The University Of California	Cisteamina con recubrimiento entérico, cistamina y derivados de las mismas
WO2009070781A1 (fr)	2007-11-30	2009-06-04	The Regents Of The University Of California	Procédés de traitement d'une stéatohépatite non alcoolique au moyen de produits à base de cystéamine
WO2011011733A2 (fr) *	2009-07-24	2011-01-27	The Regents Of The University Of Michigan	Thérapie de remplacement de facteur
US8815942B2 (en)	2010-10-20	2014-08-26	The Royal Institution For The Advancement Of Learning/Mcgill University	Combination therapy and uses thereof for treatment and prevention of parasitic infection and disease
CA2732440C (fr) *	2011-02-23	2017-10-31	Universite Laval	Analogues de la cystamine pour le traitement de la maladie de parkinson
CA2853484C (fr)	2011-10-26	2018-08-21	Seattle Children's Research Institute	Cysteamine dans le traitement d'une maladie fibreuse
US20140314841A1 (en) *	2013-04-19	2014-10-23	The United States Of America, As Represented By The Secretary, Department Of Health And Human Serv	Use of Cysteamine and Derivatives Thereof to Suppress Tumor Metastases
AR096628A1 (es) *	2013-06-17	2016-01-20	Raptor Pharmaceuticals Inc	Formulación en perlas de cisteamina de liberación retardada y métodos de preparación y uso de ella
TWI659209B (zh) *	2013-06-17	2019-05-11	地平線罕見醫學製藥有限責任公司	分析半胱胺組合物的方法
EP3143164B1 (fr) *	2014-05-16	2021-08-11	Children's Hospital Medical Center	Procédés d'évaluation de la réactivité au traitement de l'asthme sur la base de l'expression de vnn-1 et de la méthylation de promoteur
TW201618760A (zh) *	2014-11-05	2016-06-01	雷普特製藥有限公司	使用半胱胺組合物治療亨廷頓氏病之方法
CN108289867A (zh)	2015-07-02	2018-07-17	地平线孤儿病有限责任公司	Ado-抗性的半胱胺类似物和其用途
WO2017087532A1 (fr)	2015-11-16	2017-05-26	The Regents Of The University Of California	Méthodes de traitement de la stéatohépatite non alcoolique (nash) au moyen de composés de systéamine
US10143665B2 (en)	2015-11-17	2018-12-04	Horizon Orphan Llc	Methods for storing cysteamine formulations and related methods of treatment
EP3429573A4 (fr)	2016-03-17	2019-10-30	Thiogenesis Therapeutics, Inc.	Compositions servant à la libération contrôlée de cystéamine et traitement systémique de troubles sensibles à la cystéamine
ITUA20161799A1 (it) *	2016-03-18	2017-09-18	Recordati Ind Chimica E Farmaceutica S P A	Composizione farmaceutica a rilascio prolungato comprendente cisteamina o un suo sale
EP3308773A1 (fr)	2016-10-11	2018-04-18	Recordati Industria Chimica E Farmaceutica SPA	Formulations de cystéamine et de dérivés de cystéamine
WO2018093364A1 (fr) *	2016-11-16	2018-05-24	The Regents Of The University Of California	Formulations de cystéamine et de cystamine
US10251850B2 (en)	2017-01-11	2019-04-09	Lupin Limited	Process for preparation of cysteamine bitartrate
CN111683684B (zh)	2017-09-20	2024-07-02	硫创治疗公司	用于治疗半胱胺敏感性病症的方法
US20200253867A1 (en)	2017-09-22	2020-08-13	University Of Florida Research Foundation	Devices and methods for reducing cystine crystals in vivo
GB2581362A (en)	2019-02-14	2020-08-19	Univ Of Sunderland	Chemical synthesis
WO2020198529A1 (fr)	2019-03-26	2020-10-01	The Regents Of The University Ofcalifornia	Composés de type amino-thyol et amino-disulfide substitués et leurs utilisations
WO2020220036A1 (fr) *	2019-04-25	2020-10-29	Fremonta Corporation	Dispositif d'échantillonnage alimenté
EP4247356A4 (fr) *	2020-11-19	2025-01-08	Birch Therapeutics, Inc.	Formulations de cystamine et utilisations de celles-ci

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US2809918A (en)	1955-10-17	1957-10-15	Victor M Hermelin	Sustained release pharmaceutical preparations
DE2010416B2 (de)	1970-03-05	1979-03-29	Hoechst Ag, 6000 Frankfurt	Oral anwendbare Arzneiform mit Retardwirkung
US4110441A (en)	1974-04-29	1978-08-29	Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara Rt.	Gamma-l-glutamyl cholamine phosphate
FR2471186A1 (fr)	1979-12-10	1981-06-19	Roussel Uclaf	Nouveaux comprimes a delitescence colique, ainsi que leur procede de preparation
US4301146A (en)	1980-07-29	1981-11-17	G. D. Searle & Co.	Stabilization of 16-oxygenated prostanoic acid derivatives
US4728512A (en)	1985-05-06	1988-03-01	American Home Products Corporation	Formulations providing three distinct releases
US4794001A (en)	1986-03-04	1988-12-27	American Home Products Corporation	Formulations providing three distinct releases
US4959306A (en)	1986-11-28	1990-09-25	Sclavo, Inc.	Labeling design for a binding assay reagent
US5668117A (en) *	1991-02-22	1997-09-16	Shapiro; Howard K.	Methods of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with previously known medicaments
US5225202A (en)	1991-09-30	1993-07-06	E. R. Squibb & Sons, Inc.	Enteric coated pharmaceutical compositions
US5639743A (en) *	1992-11-13	1997-06-17	University Of Georgia Research Foundation	Compositions and methods for treating exocrine gland atrophy
CA2236344A1 (fr) *	1998-04-30	1999-10-30	Hemosol Inc.	Complexes hemoglobine-haptoglobine
UA69413C2 (uk)	1998-05-22	2004-09-15	Брістол-Майерс Сквібб Компані	Фармацевтична композиція, яка містить серцевину та ентеросолюбільну оболонку, фармацевтична композиція у вигляді сфероїдальних гранул, спосіб одержання сфероїдальних гранул та спосіб одержання фармацевтичної композиції
US6794414B1 (en) *	1998-06-17	2004-09-21	Yeda Research And Development Co. Ltd.	Method and compositions for treating diseases mediated by transglutaminase activity
UA73092C2 (uk) *	1998-07-17	2005-06-15	Брістол-Майерс Сквібб Компані	Таблетка з ентеросолюбільним покриттям і спосіб її приготування
AU2001237080A1 (en)	2000-02-14	2001-08-20	Len Booysen	Stabilizer unit
US20050004075A1 (en)	2000-12-13	2005-01-06	Walcom Animal Science (I.P.2) Limited	Composition for regulating animal growth, method of manufacture and use thereof
CN1144585C (zh) *	2000-12-13	2004-04-07	华扩达动物科学[I.P.2]有限公司	含有半胱胺或其盐类的促进动物快速生长的组合物及用途
GB2377874B (en)	2001-07-23	2005-06-22	Walcom Bio Chemicals Ind Ltd	Poultry feed and the use thereof
US7449451B2 (en) *	2001-08-29	2008-11-11	Premier Micronutrient Corporation	Use of multiple antioxidant micronutrients as systemic biological radioprotective agents against potential ionizing radiation risks
GB2379854B (en)	2001-09-19	2006-04-19	Walcom Animal Science	Dairy cow feed and the use thereof
CN1596111A (zh) *	2001-11-29	2005-03-16	桑得医药品公司	减轻化疗引起的不良效果的组合物及方法
KR20040078663A (ko) *	2002-01-04	2004-09-10	사운드 파마슈티칼스 인코퍼레이티드	난청의 치료 방법
GB2386817B (en) *	2002-02-20	2006-08-23	Walcom Animal Science	Feed for fish and use therof
US8017651B2 (en) *	2002-11-22	2011-09-13	Bionexus, Ltd.	Compositions and methods for the treatment of HIV-associated fat maldistribution and hyperlipidemia
GB2398497A (en) *	2003-02-19	2004-08-25	Walcom Animal Science	Composition for improving immunity of animals
US8029822B2 (en) *	2003-05-22	2011-10-04	Osmotica Kereskedelmi és Seolgáltató KFT	Rupturing controlled release device having a preformed passageway
WO2005049002A1 (fr)	2003-11-19	2005-06-02	Omega Bio-Pharma International Ltd.	Produits et procedes permettant d'ameliorer le metabolisme de l'alcool et d'attenuer les effets du syndrome appele « gueule de bois »
RU2367423C2 (ru) *	2003-12-19	2009-09-20	ОМЕГА БИО-ФАРМА (Ай.Пи. 3) ЛИМИТЕД	Композиции и способы для лечения диабета
US20050209441A1 (en)	2004-03-22	2005-09-22	Lile Jackson D	Process for promoting proper folding of human serum albumin using a human serum albumin ligand
CN1976691B (zh)	2004-05-03	2010-10-13	奥加生物药业(I.P.3)有限公司	半胱胺用于治疗高胆固醇血症和糖尿病并发症
CA2605631A1 (fr)	2005-04-20	2006-10-26	Fred Hutchinson Cancer Research Center	Procedes, compositions et articles manufactures permettant d'ameliorer la capacite de survie de cellules, de tissus, d'organes et d'organismes
AR057623A1 (es)	2005-11-28	2007-12-05	Omega Bio Pharma H K Ltd	Materiales y metodos para el tratamiento de las infecciones virales
KR101394245B1 (ko)	2005-12-30	2014-05-14	에스케이바이오팜 주식회사	아이속사졸 유도체 및 이의 용도
US20070172514A1 (en)	2006-01-20	2007-07-26	Francis Chi	Materials and methods for improving livestock productivity
ES2388310T7 (es) *	2006-01-27	2017-05-03	The Regents Of The University Of California	Cisteamina con recubrimiento entérico, cistamina y derivados de las mismas
WO2009070781A1 (fr) *	2007-11-30	2009-06-04	The Regents Of The University Of California	Procédés de traitement d'une stéatohépatite non alcoolique au moyen de produits à base de cystéamine
CN102006785A (zh)	2008-02-17	2011-04-06	华扩达动物科学(I.P.3)有限公司	改善虾健康的材料和方法

2007
- 2007-01-26 ES ES07762690.1T patent/ES2388310T7/es active Active
- 2007-01-26 MX MX2015013747A patent/MX382184B/es unknown
- 2007-01-26 US US11/990,869 patent/US8026284B2/en active Active
- 2007-01-26 EA EA200801752A patent/EA023971B1/ru not_active IP Right Cessation
- 2007-01-26 PT PT121698666T patent/PT2535044T/pt unknown
- 2007-01-26 MX MX2008009647A patent/MX2008009647A/es active IP Right Grant
- 2007-01-26 PL PL07762690T patent/PL1919458T6/pl unknown
- 2007-01-26 BR BRPI0707277-5A patent/BRPI0707277B1/pt active IP Right Grant
- 2007-01-26 DK DK12169866.6T patent/DK2535044T3/da active
- 2007-01-26 CA CA2640531A patent/CA2640531C/fr active Active
- 2007-01-26 WO PCT/US2007/002325 patent/WO2007089670A2/fr not_active Ceased
- 2007-01-26 ES ES12169866T patent/ES2774755T3/es active Active
- 2007-01-26 PL PL12169866T patent/PL2535044T3/pl unknown
- 2007-01-26 EP EP12169866.6A patent/EP2535044B1/fr not_active Revoked
- 2007-01-26 EA EA201600089A patent/EA201600089A1/ru unknown
- 2007-01-26 EP EP07762690.1A patent/EP1919458B3/fr active Active
- 2007-01-26 DK DK07762690.1T patent/DK1919458T6/en active
- 2007-01-26 SI SI200732147T patent/SI2535044T1/sl unknown
- 2007-01-26 PT PT07762690T patent/PT1919458E/pt unknown
- 2007-01-26 SI SI200731035T patent/SI1919458T1/sl unknown
- 2007-01-26 AU AU2007210005A patent/AU2007210005C1/en active Active
- 2007-01-26 LT LTEP12169866.6T patent/LT2535044T/lt unknown
- 2007-01-26 EP EP19206788.2A patent/EP3659588A1/fr active Pending
- 2007-01-26 HU HUE12169866A patent/HUE049307T2/hu unknown
2008
- 2008-07-24 IL IL193044A patent/IL193044A/en active IP Right Grant
2011
- 2011-07-25 US US13/190,396 patent/US8129433B2/en not_active Expired - Fee Related
2012
- 2012-02-17 US US13/399,900 patent/US20120237599A1/en not_active Abandoned
2014
- 2014-03-05 FR FR14C0018C patent/FR14C0018I1/fr active Active
- 2014-03-05 NL NL300649C patent/NL300649I2/nl unknown
- 2014-03-05 LU LU92389C patent/LU92389I2/fr unknown
- 2014-11-28 US US14/555,993 patent/US20150283100A1/en not_active Abandoned
2015
- 2015-06-26 US US14/752,383 patent/US9198882B2/en active Active
- 2015-06-26 US US14/752,499 patent/US9192590B2/en active Active
- 2015-11-24 US US14/950,234 patent/US9511039B2/en active Active
2016
- 2016-07-27 US US15/220,693 patent/US9750708B2/en active Active
- 2016-07-29 US US15/224,414 patent/US9795578B2/en active Active
- 2016-10-27 US US15/336,405 patent/US9814689B2/en active Active
2017
- 2017-07-21 US US15/656,903 patent/US9925158B2/en active Active
- 2017-07-21 US US15/656,884 patent/US9925157B2/en active Active
- 2017-07-21 US US15/656,863 patent/US9925156B2/en active Active
2018
- 2018-03-15 US US15/922,520 patent/US10485774B2/en active Active
2019
- 2019-11-14 US US16/684,000 patent/US11311507B2/en active Active
2020
- 2020-03-16 CY CY20201100240T patent/CY1122943T1/el unknown

Also Published As

Publication number	Publication date
NL300649I2 (fr)	2017-01-03
SI1919458T1 (sl)	2012-11-30
PT1919458E (pt)	2012-08-23
HUE049307T2 (hu)	2020-09-28
US8026284B2 (en)	2011-09-27
EP2535044A1 (fr)	2012-12-19
US9925156B2 (en)	2018-03-27
IL193044A (en)	2016-04-21
MX2008009647A (es)	2008-09-25
PT2535044T (pt)	2020-03-26
AU2007210005A1 (en)	2007-08-09
DK1919458T5 (en)	2014-03-17
US20160151310A1 (en)	2016-06-02
MX382184B (es)	2025-03-13
CA2640531A1 (fr)	2007-08-09
FR14C0018I1 (fr)	2014-04-11
WO2007089670A2 (fr)	2007-08-09
PL1919458T6 (pl)	2017-10-31
WO2007089670A3 (fr)	2007-11-29
US10485774B2 (en)	2019-11-26
US9750708B2 (en)	2017-09-05
CY1122943T1 (el)	2021-10-29
EP1919458A2 (fr)	2008-05-14
EA200801752A1 (ru)	2008-12-30
US20090076166A1 (en)	2009-03-19
US9795578B2 (en)	2017-10-24
US9511039B2 (en)	2016-12-06
EA201600089A1 (ru)	2017-01-30
EP3659588A1 (fr)	2020-06-03
US8129433B2 (en)	2012-03-06
US20120237599A1 (en)	2012-09-20
US20150290149A1 (en)	2015-10-15
US11311507B2 (en)	2022-04-26
ES2388310T7 (es)	2017-05-03
US20160331691A1 (en)	2016-11-17
US20170042845A1 (en)	2017-02-16
EA023971B1 (ru)	2016-08-31
US20200338033A1 (en)	2020-10-29
US20170319524A1 (en)	2017-11-09
EP1919458A4 (fr)	2010-05-26
US20160331705A1 (en)	2016-11-17
LT2535044T (lt)	2020-04-10
BRPI0707277A2 (pt)	2011-04-26
US9814689B2 (en)	2017-11-14
BRPI0707277B1 (pt)	2021-07-13
US20150290150A1 (en)	2015-10-15
US20120015038A1 (en)	2012-01-19
SI2535044T1 (sl)	2020-06-30
EP1919458B3 (fr)	2017-01-11
AU2007210005C1 (en)	2014-01-23
US9925157B2 (en)	2018-03-27
CA2640531C (fr)	2017-01-03
US20170319522A1 (en)	2017-11-09
DK2535044T3 (da)	2020-03-23
ES2388310T3 (es)	2012-10-11
EP2535044B1 (fr)	2019-12-18
PL2535044T3 (pl)	2020-06-29
US20150283100A1 (en)	2015-10-08
US20190060264A1 (en)	2019-02-28
US20170319523A1 (en)	2017-11-09
IL193044A0 (en)	2009-02-11
US9925158B2 (en)	2018-03-27
ES2774755T3 (es)	2020-07-22
US9198882B2 (en)	2015-12-01
US9192590B2 (en)	2015-11-24
EP1919458B1 (fr)	2012-07-11
DK1919458T3 (da)	2012-08-20
PL1919458T3 (pl)	2012-12-31
AU2007210005B2 (en)	2013-09-05
DK1919458T6 (en)	2017-03-27

Publication	Publication Date	Title
LU92389I2 (fr)	2015-10-29	Cystéamine
DK2096917T3 (da)	2014-09-15	Cyclopamin-analoger
DK2081937T3 (da)	2012-10-01	Triazolopyridazin-proteinkinasemodulatorer
DE602006019782D1 (de)	2011-03-03	Kapselperforationsmodul
DE602007002544D1 (de)	2009-11-05	Nuancierungsmittel
DE602007008423D1 (de)	2010-09-23	Flüssigkeitshärtung
DE602007013937D1 (de)	2011-05-26	Torantagonisten
DE602007009267D1 (de)	2010-10-28	Reifenaufblasverfahren
DE602007009650D1 (de)	2010-11-18	Spiroindolinonderivate
DE602007003893D1 (de)	2010-02-04	Kippambossanordnung
AT504580A3 (de)	2008-07-15	Scan-einrichtung
DE602007006947D1 (de)	2010-07-15	Pyridopyrimidinonderivate
DE602007000258D1 (de)	2009-01-02	Kassetteneinspannmechanismus
DE602007001280D1 (de)	2009-07-30	Getränkeextraktor
DE602007009337D1 (de)	2010-11-04	Tastfeedbackvorrichtung
DK1984239T3 (da)	2013-12-02	Dobbeltlags-tørdragt
DE602007008400D1 (de)	2010-09-23	Kaliummonopersulfatlösungen
DE602007010359D1 (de)	2010-12-16	Azaspiroderivate
DE602006020192D1 (de)	2011-03-31	Riemenscheibenanorndung
DE502007001629D1 (de)	2009-11-12	Rfahren
ATE546437T1 (de)	2012-03-15	Aminomethyl-4-imidazole
DE502007000218D1 (de)	2008-12-18	nsetzungen
DE602007000501D1 (de)	2009-03-12	Breitbandrichtkoppler
DE502007002453D1 (de)	2010-02-11	Kunstoffverdichtergehäuse
DE602007001098D1 (de)	2009-06-25	Spindelmäheinheit